2018 Webinars
Collapse Advancing Patient Care in NSCLC: Breaking Down Barriers (CE Available)

This webinar series includes the presentations and the audience QAs recorded from the live broadcast and the associated slide handouts. If you would like continuing education credit for the webinars, click on the links in the table below to access the webinars + CME/CMLE or webinars + SAM


Speakers:

Neal Lindeman, MD Eric H. Bernicker, MD Dara Aisner, MD, PhD
Lynette M. Sholl, MD Sinchita Roy-Chowdhuri, MD, PhD Christopher R. Gilbert, DO, MS, FCCP

 

Series Description: Over the past 10 years, understanding of oncogenic signal transduction pathways has fundamentally altered the treatment paradigm for advanced NSCLC, leading to personalized treatment. As a result, diagnosing and treating NSCLC has evolved from a relatively simple “one-size-fits-all” approach to an extremely complex algorithm that requires personalized treatment plans. 

This free online learning experience is aimed at breaking down barriers to testing and treatment in Non-Small Cell Lung Cancer (NSCLC). Hear from world-renowned experts and explore best practices in test ordering, sample collection, and test interpretation with the goal of improving patient care.

Webinars include: (Click "Topic" tab for descriptions)

  • Molecular Testing Guideline for Selection of Lung Cancer Patients - Revision
    Speaker: Neal Lindeman 
    Recorded: May 29, 2018
  • Best Practices in NSCLC Small Specimen Collection for Clinicians 
    Speaker: Eric Bernicker 
    Recorded: June 20, 2018
  • Best Practices in Small Specimen Management for Laboratory Professionals
    Speaker: Dara Aisner
    Recorded: August 16, 2018
  • Liquid Biopsies – Promises and Pitfalls 
    Speaker: Lynette Sholl
    Recorded: October 9, 2018
  • Best Practices in Test Ordering 
    Speakers: Sinchita Roy-Chowdhuri and Christopher R. Gilbert
    Recorded: December 13, 2018

Duration: 5 hr

Level of Instruction: Basic

  • Add the entire series into your classroom by clicking "Add to Basket" button located on the right.
  • Add individual webinars into your classroom by clicking on the "Purchase Individual Topics" button on the right. Select the particular webinar(s) that you would like and proceed through checkout.

 

This webinar is a five-part series aimed at breaking down barriers to NSCLC testing and treatment. If you'd like more information about the series go here.

Supported by an educational grant provided by AstraZeneca


Click on the links below to access continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE Maximum 5.0

Webinar + CME/CMLE
(Free for all)

SAM Maximum 5.0

Webinar + SAM
(Free for all)

Continuing Education Credit must be purchased and claimed by May 29, 2019

You may also be interested in:

 

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Formats Available: NSCLC Series 1
Original Course Date: May 29, 2018
MORE INFOMORE INFO Advancing Patient Care in NSCLC: Breaking Down Barriers (CE Available)
Collapse AMP/ASCO/CAP Standards and Guidelines of Somatic Variant Interpretation and Reporting (CE available)

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


Description:

In January 2017, a working group comprised of representatives from the Association for Molecular Pathology (AMP), College of American Pathologists (CAP), American Society of Clinical Oncology (ASCO), and American College of Medical Genetics and Genomics (ACMG) published the guidelines for the interpretation and reporting of somatic variants. This subject matter expert panel comprised of investigators with expertise in molecular pathology, medical genetics, and clinical oncology, assessed the current status of NGS-based testing for cancer and established standardized classification, annotation, interpretation, and reporting conventions for sequence variants associated with cancer.

In this webinar, Dr. Marilyn M. Li summarizes the guideline and provides a number of examples illustrating how to implement the classification system.


Practice Guideline Available Here

Speaker: Marilyn M. Li, MD

Host: Antonia R. Sepulveda, MD, PhD

Duration: 1 hr

Level of Instruction: Basic

 

Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Just $5.00 USD for AMP members)

SAM 1.0

Purchase Webinar + SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by January 26, 2021

 

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 
Formats Available: Streaming
Original Course Date: January 26, 2018
MORE INFOMORE INFO AMP/ASCO/CAP Standards and Guidelines of Somatic Variant Interpretation and Reporting (CE available)
Collapse Mutational Pattern Recognition in Chronic Myeloid Neoplasms (CMNs) (CE available)

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


Description:

This presentation summarizes the findings of the Association for Molecular Pathology Chronic Myeloid Neoplasm Working Group. Chronic myeloid neoplasms (CMNs) are defined as a complex group of hematopoietic disorders, encompassing myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), the overlap entities (MDS/MPNs), and systemic mastocytosis. The goal of this group was to distill the vast amounts of literature on the mutational profiles of the CMNs into high impact information that would aid molecular pathologists in the development of next generation sequencing (NGS) myeloid panels. This work identifies 34 genes as the minimum recommended testing list and provides information on the frequency of these genes in the various CMNs as well as their prognostic and therapeutic import. In addition, the findings highlight the recurrent patterns of mutational clonal evolution in these patients, uncovering critical insight into the biology of these neoplasms.


Practice Guideline Available Here

Speaker: Annette S. Kim, MD, PhD

Moderator: Todd W. Kelley, MD

Duration: 1 hr

Level of Instruction: Intermediate


Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Just $5.00 USD for AMP members)

SAM 1.0

Purchase Webinar + SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by July 19, 2021

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

 

 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written p

Formats Available: Kim Presentation
Original Course Date: July 19, 2018
MORE INFOMORE INFO Mutational Pattern Recognition in Chronic Myeloid Neoplasms (CMNs) (CE available)
Collapse Practical Considerations for the Validation of Next-Generation Sequencing-Based Oncology Panels (CE Available)

   This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


                                                                  

Speaker:
Lawrence J. Jennings, MD, PhD


Moderator: 
Antonia R. Sepulveda, MD, PhD

 

 

Description: Validation of NGS-based testing for oncology panels can be challenging given the many steps and wide range of targeted mutations. In this presentation, Dr. Jennings will discuss the recent AMP/CAP guideline recommendations for validation and review practical ways to provide documented evidence with the clinical NGS reports.


Practice Guideline Available Here

Duration: 1 hr

Level of Instruction: Basic


Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Just $5.00 USD for AMP members)

SAM 1.0

Purchase Webinar + SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by April 25, 2021

 

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 
Formats Available: Jennings Webinar
Original Course Date: April 25, 2018
MORE INFOMORE INFO Practical Considerations for the Validation of Next-Generation Sequencing-Based Oncology Panels (CE Available)
Collapse Recommendations for Clinical <i>CYP2C19</i> Genotyping Allele Selection (CE available)

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


Description:

In this webinar, Dr. Karen Weck will present the recommendations of The AMP Pharmacogenomics Working Group of the Clinical Practice Committee for inclusion of variants in CYP2C19 genotyping panels. The working group has published consensus, evidence-based recommendations using criteria such as allele function, population frequency, and availability of reference materials. The recommendations include a Tier 1 minimum set of alleles and defining variants that should be included in all clinical CYP2C19 PGx tests, and a Tier 2 list of additional optional alleles that do not currently meet all of the criteria for inclusion in Tier 1. These recommendations are intended to aid clinical laboratory professionals when designing and validating CYP2C19 genotyping assays, promote standardization of testing across different laboratories, and complement existing clinical guidelines for pharmacogenetic testing.


Practice Guideline Available Here

Speaker: Karen E. Weck, MD

Host: Joshua Deignan, PhD

Duration: 1 hr

Level of Instruction: Basic

 

Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Just $5.00 USD for AMP members)

SAM 1.0

Purchase Webinar + SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by March 21, 2021

 

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 
Formats Available: Weck Presentation
Original Course Date: March 21, 2018
MORE INFOMORE INFO Recommendations for Clinical <i>CYP2C19</i> Genotyping Allele Selection (CE available)
Collapse Revised PAMA Requirements: What Hospital Outreach Laboratories Need to Know to Comply (CE Available)
Webinar hosted by the AMP Economic Affairs Committee

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE. 


Description: On November 1, the Centers for Medicare and Medicaid Services (CMS) finalized proposed changes to the Physician Fee Schedule and Quality Payment Program for 2019. The final rule includes sections that will be effective on January 1, 2019, and directly address the Protecting Access to Medicare Act (PAMA) and the Clinical Lab Fee Schedule (CLFS). CMS revises the definition of “Applicable Laboratories,” by utilizing the CMS-1450 14x Type of Bill which is specific to hospital outreach laboratories. The use of this bill type will result in an increase in AMP member laboratories required to report private payer data to CMS. During this webinar, an overview of PAMA and the final rule changes will be provided. The webinar will also provide guidance on how to determine whether or not your laboratory qualifies as an applicable laboratory, timelines for collecting and reporting data, and resources available to assist laboratories through this process. During and after the webinar we encourage attendees to submit their questions. These questions and answers will be compiled into a document and will be available as a supplement to the archived version of this webinar.

Background: CMS released the final rule implementing the CLFS rate setting provision of Protecting Access to Medicare Act (PAMA) in June of 2016. Laboratories defined as “applicable laboratories” are required to report HCPCS laboratory codes, associated private payer rates, and volume data if they meet certain revenue thresholds from laboratory and physician services during a collection period. CMS takes the weighted median of the data submitted to determine the price for services on the Clinical Laboratory Fee Schedule (CLFS). To watch an archived webinar on the PAMA final rule, please visit (free to members and non-members): http://educate.amp.org/store/seminar/seminar.php?seminar=99261


Speakers: Erika Miller, JD, Senior Vice President and Counsel, CRD Associates, Consultant to AMP’s Economic Affairs Committee (EAC)

Moderator: Samuel K. Caughron, MD, Chair, AMP Economic Affairs Committee 

Duration: 1hr

Level of Instruction: Basic


Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Just $5.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by December 20, 2021
 

You may also be interested in:

 

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Formats Available: Streaming
Original Course Date: December 20, 2018
MORE INFOMORE INFO Revised PAMA Requirements: What Hospital Outreach Laboratories Need to Know to Comply (CE Available)
Collapse Standards and Guidelines for Validating Next Generation Sequencing Bioinformatics Pipelines: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists (CE Available)

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


Description:

Bioinformatics pipelines are integral components of next-generation sequencing (NGS) assays. Until recently, a lack of guidelines caused significant variability in how pipelines were validated in the molecular genetics and pathology community. To address this important issue, Association for Molecular Pathology (AMP) with liaison representation from the College of American Pathologists (CAP), and the American Medical Informatics Association (AMIA) released Standards and Guidelines for Validating Next-Generation Sequencing Bioinformatics Pipelines in January 2018. In this webinar, Dr. Somak Roy and Dr. Alexis Carter will highlight some of the important recommendations.


Practice Guideline Available Here

Speakers: Somak Roy, MD and Alexis B. Carter, MD

Moderator: Justin Zook, PhD

Duration: 1 hr

Level of Instruction: Basic

 

Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Just $5.00 USD for AMP members)

SAM 1.0

Purchase Webinar + SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by April 20, 2021

 

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 
Formats Available: Roy and Carter Presentation
Original Course Date: April 20, 2018
MORE INFOMORE INFO Standards and Guidelines for Validating Next Generation Sequencing Bioinformatics Pipelines: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists (CE Available)
Collapse The ABCs of CPT<sup>®</sup> Coding (CE Available)
A Webinar Presented by the AMP Economic Affairs Committee

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


Description:

Knowledge of the coding structure of molecular medicine is crucial as these codes are incorporated and used by insurers to identify the services you provide to patients and understanding the basics of CPT® coding will benefit your laboratory practice and management. The American Medical Association (AMA) Current Procedural Terminology (CPT®) coding system is used throughout the United States as a main system of coding for health care services, including laboratory and pathology procedures. The AMP Economic Affairs Committee (EAC) is intimately involved in this process, both by submitting code change applications regularly but also by occupying a rotating seat on the Pathology Coding Caucus, which reviews and provides recommendations to the AMA CPT® Editorial Panel on applications for new or revised pathology and laboratory services. During this webinar, AMP members will be provided with a better understanding of the intricacies of the CPT® coding structure and process for laboratory and pathology codes. This webinar will also educate members by providing resources and tips for submitting your own code change application.


Speakers: Anthony N. Sireci, MD;  Aaron D. Bossler, MD, PhD; and Victoria M. Pratt, PhD

Moderator: Cecilia S. Yeung, MD

Duration: 1 hr

Level of Instruction: Basic


Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Just $5.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by Sept 18, 2021

 

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Formats Available: Streaming
Original Course Date: September 18, 2018
MORE INFOMORE INFO The ABCs of CPT<sup>®</sup> Coding (CE Available)
Collapse Tumor Mutational Burden: Best Practices to Address Clinical and Technical Challenges (CE Available)

This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA. If you would like continuing education credit for the webinar, click on the links in the table below to access the webinar + CME/CMLE or webinar + SAM


Speaker:

Jonathan Nowak, MD, PhD 

Moderator:

Jeremy Segal, MD, PhD

 

Description: This webinar will cover the methodology for calculating tumor mutational burden (TMB) and will review technical considerations that can impact TMB calculation. The utility of detecting the underlying mutational processes that determine a tumor's mutational burden will also be discussed. The course will cover an overview of immunotherapy drugs, targets, and tumor types for which TMB has been used as a biomarker.

Duration: 1 hr

Level of Instruction: Basic

This webinar is part 2 of a three-part series exploring how measuring tumor mutational burden can improve patient care. If you'd like more information about the series go here.

This program has been supported through an educational grant from Bristol-Myers Squibb.


Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Free for all)

SAM 1.0

Purchase Webinar + SAM

(Free for all)

Continuing Education Credit must be purchased and claimed by December 31, 2020

 

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

 

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 
Formats Available: Nowak Presentation
Original Course Date: August 28, 2018
MORE INFOMORE INFO Tumor Mutational Burden: Best Practices to Address Clinical and Technical Challenges (CE Available)
Collapse Tumor Mutational Burden: Clinical and Diagnostic Utilization in Oncology (CE Available)

This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA. If you would like continuing education credit for the webinar, click on the links in the table below to access the webinar + CME/CMLE or webinar + SAM


Speaker:

Lauren Ritterhouse MD, PhD

Moderator:

Susan Hsiao MD, PhD

 

Description:  This webinar will cover the background and rationale for the use of tumor mutational burden (TMB) as a biomarker for immunotherapy in oncology. The various biomarkers that have been evaluated for immunotherapy will be explored and a discussion of TMB’s role and use in oncology will be made. The course will cover an overview of immunotherapy drugs, targets, and tumor types for which TMB has been used as a biomarker.

Duration: 1 hr

Level of Instruction: Basic

 

This webinar is part 1 of a three-part series exploring how measuring tumor mutational burden can improve patient care. If you'd like more information about the series go here

This program has been supported through an educational grant from Bristol-Myers Squibb.


Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Free for all)

SAM 1.0

Purchase Webinar + SAM

(Free for all)

Continuing Education Credit must be purchased and claimed by December 31, 2020

 

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

 

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 

 

 

 
Formats Available: Ritterhouse Presentation
Original Course Date: June 27, 2018
MORE INFOMORE INFO Tumor Mutational Burden: Clinical and Diagnostic Utilization in Oncology (CE Available)
Collapse Tumor Mutational Burden: Result Reporting and Application to Improve Patient Care (CE Available)

This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA. If you would like continuing education credit for the webinar, click on the links in the table below to access the webinar + CME/CMLE or webinar + SAM


Speaker:

      Ahmet Zehir, PhD     

Moderator:

Jonathan Nowak, MD, PhD

Description: As tumor mutational burden (TMB) is gaining traction as a predictive biomarker for immunotherapy, the challenge of reporting TMB back to the treating oncologists and patients in an informative way still exists. In this webinar, we will discuss strategies of implementing TMB in the clinical laboratory, how different TMB values reported from various assays compare to each other, and how to communicate the results in a clear way.

Duration: 1 hr

Level of Instruction: Basic

This webinar is part 3 of a three-part series exploring how measuring tumor mutational burden can improve patient care. If you'd like more information about the series go here.

This program has been supported through an educational grant from Bristol-Myers Squibb.


Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Free for all)

SAM 1.0

Purchase Webinar + SAM

(Free for all)

Continuing Education Credit must be purchased and claimed by December 31, 2020

 

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 
Formats Available: Zehir Presentation
Original Course Date: September 26, 2018
MORE INFOMORE INFO Tumor Mutational Burden: Result Reporting and Application to Improve Patient Care (CE Available)
Collapse WHO 2016 Updates: Acute Leukemias (CE Available)

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


Description:

This webinar will review the most recent revision of the World Health Organization (WHO) classification of acute leukemia with a particular focus on acute myeloid leukemia. A summary of changes to the classification of lymphoblastic leukemia/lymphoma and acute leukemias of ambiguous lineage will also be summarized.

A collaborative educational event presented by Association for Molecular Pathology (AMP) and Society for Hematopathology (SH).


Speaker: Daniel A. Arber, MD

Host: Mark D. Ewalt, MD

Duration: 1 hr

Level of Instruction: Intermediate

Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase CME/CMLE

(Just $5.00 USD for AMP members)

SAM 1.0

Purchase SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by January 22, 2021

 

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 

 
Formats Available: Arber Presentation
Original Course Date: January 22, 2018
MORE INFOMORE INFO WHO 2016 Updates: Acute Leukemias (CE Available)
Collapse WHO 2016 Updates: B-Lymphoid Neoplasms (and how practice is changing) (CE Available)

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


Description:

In this presentation, Dr. Hsi will review important changes in the recently published update to the 2016 WHO classification of B-cell neoplasms. Topics include monoclonal B-cell lymphocytosis, in situ follicular neoplasia, pediatric type follicular lymphoma, and provisional entities such as large B-cell lymphoma with IRF rearrangement and EBV+ mucocutaneous ulcer. The appropriate molecular characterization of diffuse large B-cell lymphomas and high grade B-cell lymphomas will also be discussed.

A collaborative educational event presented by Association for Molecular Pathology (AMP) and Society for Hematopathology (SH).


Speaker: Eric D. Hsi, MD

Host: Mark D. Ewalt, MD

Duration: 1 hr

Level of Instruction: Basic

 

Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase CME/CMLE

(Just $5.00 USD for AMP members)

SAM 1.0

Purchase SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by February 2, 2021

 

* You may not submit SAMs and CME/CMLE credit for the same content.


You might also be interested in:

 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 
Formats Available: Hsi Presentation
Original Course Date: February 02, 2018
MORE INFOMORE INFO WHO 2016 Updates: B-Lymphoid Neoplasms (and how practice is changing) (CE Available)
Collapse WHO 2016 Updates: Myeloproliferative Neoplasms (CE Available)

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


In this webinar, Dr. Tracy George will discuss updates in the classification of myeloproliferative neoplasms, also including eosinophilic neoplasms with recurring mutations, and mastocytosis. This includes new criteria for accelerated phase (response-to-TKI criteria) in chronic myeloid leukemia, WHO 2016 criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis, as well as eosinophilic neoplasms with and without recurring mutations. Updates in the diagnosis of mastocytosis, now its own chapter again in the WHO 2016 classification, will also be explained.

A collaborative educational event presented by Association for Molecular Pathology (AMP) and Society for Hematopathology (SH).


Speaker: Tracy I. George, MD

Host: Mark D. Ewalt, MD

Duration: 1 hr

Level of Instruction: Basic

 

Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase CME/CMLE

(Just $5.00 USD for AMP members)

SAM 1.0

Purchase SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by March 1, 2021

 

* You may not submit SAMs and CME/CMLE credit for the same content.


You might also be interested in:

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation

 
Formats Available: George Presentation
Original Course Date: March 01, 2018
MORE INFOMORE INFO WHO 2016 Updates: Myeloproliferative Neoplasms (CE Available)
Collapse WHO 2016 Updates: Nodal Peripheral T-cell Lymphomas (CE Available)

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


Description:

Following a brief overview on the difficulties encountered in the definition of the epidemiology, classification, diagnosis, prognosis, and therapy of peripheral T/NK-cell lymphomas, nodal peripheral T-cell lymphomas (PTCLs) will be discussed in detail. These neoplasms account for more than 60% of tumours stemming from peripheral T-lymphocytes. In the Revised WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, they correspond to 4 entities: PTCL, not otherwise specified (NOS), PTCLs related to follicular helper T-lymphocytes (FTH), ALK+ anaplastic large cell lymphoma (ALCL), and ALK- ALCL. Tumour related to TFH cells represent a new category, including angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma and neoplasms lacking the morphologic characteristics of the previous two subtypes but also stemming from TFH-elements. The latter group was in the past included among PTCLs/NOS. ALK- ALCL was promoted from provisional to accepted entity because of emerging molecular evidences. In addition, the new provisional category of breast implant-associated ALCL was included. Most of the changes introduced in the Revised WHO Classification by comparison with the 2008 fourth edition are due to the extensive application of molecular techniques, including gene expression profiling and next generation sequencing. All the changes will be highlighted and discussed.

A collaborative educational event presented by Association for Molecular Pathology (AMP) and Society for Hematopathology (SH).


Speaker: Stefano A. Pileri, MD

Host: Jennifer Dunlap, MD

Duration: 1 hr

Level of Instruction: Intermediate

Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase CME/CMLE

(Just $5.00 USD for AMP members)

SAM 1.0

Purchase SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by January 18, 2021

 

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 
Formats Available: Pileri Presentation
Original Course Date: January 18, 2018
MORE INFOMORE INFO WHO 2016 Updates: Nodal Peripheral T-cell Lymphomas (CE Available)
Collapse WHO Update 2016: Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms (CE Available)

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


Description:

This webinar reviews the updated diagnostic criteria of myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms according to the recently revised WHO Classification, with emphasis on significant changes from the prior (2008) WHO Classification. New and revised entities within this group of diseases will be presented and the appropriate testing required to correctly diagnose these neoplasms will be discussed.


Speaker: Robert P. Hasserjian, MD

Host: Jennifer Dunlap, MD

Duration: 1 hr

Level of Instruction: Basic

 

If you would like continuing education credit, click on the links below.

Credit Type

Number of Credit Hours

Click on link to purchase:

CME/CMLE

1.0

Purchase webinar + CME/CMLE

(Just $5.00 USD for AMP members)

SAM

1.0

Purchase webinar + SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by February 15, 2021.

 

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 
Formats Available: Hasserjian Presentation
Original Course Date: February 15, 2018
MORE INFOMORE INFO WHO Update 2016: Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms (CE Available)